Lyra Therapeutics, Inc.
LYRACIK 0001327273 · Quarterly mode · latest period FY2025 (Q4) (ending 2025-12-31) · sourced from SEC EDGAR
At a glance · FY2025 (Q4)
Quality Score
Quality score
6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration
- Profitability100ROIC 325.8% (10% = solid, 20%+ = moat)
- Liquidity60Current Ratio 1.71 (above 1.5 = solid)
- Leverage0Insufficient data
- Efficiency0Asset Turnover 0.01x (1.0+ = capital-efficient)
- Growth0Revenue YoY -96.7% (10% = solid, 25%+ = elite)
- Margin Trend0Op Margin -24948.0% · trend -5203.4pts (4Q avg vs prior 4Q)
Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.
Capital allocation · trailing 4 quarters
how the company spent its cashBalance sheet · 2025-12-31
latest filed snapshotRecent performance · 28 quarters
Drill down
LYRA Sankey
See Lyra Therapeutics, Inc.'s revenue flow into every line item of the income statement and balance sheet — every dollar accounted for, with prior-period comparison.
Open SankeyLYRA Charts
28 quarters of historical line items — Income, Cash Flow, Balance Sheet, plus margins. Click any chart for the trend dialog.
Open ChartsLYRA Key Metrics
EPS, BVPS, FCF/Share, ROE, ROA, ROIC, D/E, Current Ratio, Quick Ratio, Asset Turnover — 10 CFA-grade fundamentals derived from EDGAR data.
Open Key Metrics